Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:49 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
An Open Label Treatment Extension Study of AMG 706
NCT00360867 · Amgen · PHASE2 · terminated · last registry update 2015-10-15 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Amgen decision” | – | Registry record, Amgen |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against KIT within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2016-08-26Phase 3 first posted: Goethe University, Rituximab + Nelarabine (NCT02881086)
- 2016-08-02Phase 3 first posted: Merck Sharp & Dohme LLC, Pembrolizumab + Axitinib (NCT02853331)
- 2016-06-23Phase 3 first posted: Eisai Inc., Lenvatinib + Everolimus (NCT02811861)
- 2016-04-13Phase 3 first posted: UMC Utrecht, Ceftriaxone + Macrolide + Moxifloxacin or Levofloxacin (NCT02735707)
- 2016-04-01Results posted on the registry: Georgetown University, Temozolomide + ABT-888 (NCT01205828)
- 2016-02-17Phase 3 first posted: Pfizer, Avelumab (MSB0010718C) + Axitinib (AG-013736) (NCT02684006)
- 2015-10-15Phase 3 first posted: Bristol-Myers Squibb, Nivolumab + Sorafenib (NCT02576509)
- 2015-09-29Phase 3 first posted: SillaJen, Inc., Pexastimogene Devacirepvec (Pexa Vec) + Sorafenib (NCT02562755)
- 2015-09-01Results posted on the registry: National Cancer Institute (NCI), cetuximab + sorafenib tosylate (NCT00939627)
- 2015-07-20Phase 3 first posted: National Cancer Institute (NCI), Cediranib + Cediranib Maleate (NCT02502266)
- 2015-05-18Phase 3 first posted: National Cancer Institute (NCI), Carboplatin + Cediranib Maleate (NCT02446600)
- 2015-04-14Results posted on the registry: National Cancer Institute (NCI), Carboplatin + Cisplatin (NCT00453154)
- 2015-04-10Phase 3 first posted: Heikki Joensuu, Imatinib (NCT02413736)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision